Treatment of CML is based on tyrosine kinase inhibitors, especially Imatinib.   87  Imatinib has revolutionized CML therapy by suppressing the tyrosine kinase activity of ABL-BCR, which leads to tumor cell death.   88. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.